Peptris

For physicians, the pace of new drug approvals is critical. Peptris addresses the core bottleneck: the slow, expensive preclinical discovery phase. Traditional pharma R&D efficiency is falling while costs rise. Peptris reverses this trend with a proprietary AI platform that integrates unsupervised learning and generative AI. Instead of years of wet lab trial and error, the platform rapidly designs and screens vast virtual libraries of molecules to identify candidates that are potent, safe, and selective. Its impact is tangible. The platform is used across three critical pathways: discovering Novel Chemical Entities (NCEs), repurposing existing drugs for new indications, and rescuing clinically safe molecules for new targets. The most compelling proof for clinicians is its success with PEPR-124, a repurposed drug for Duchenne Muscular Dystrophy (DMD). Using its AI, Peptris identified this candidate, which has since been licensed and granted Orphan Drug Designation by the USFDA, advancing it to a Phase 2-ready state. This demonstrates a clear path from AI model to a viable therapeutic that could one day be in your hands.